RYTHM stock price surges 23% due to revision of Green Thumb licensing agreement

LootboxPhobia · 2026-04-01T22:33:03+00:00

RYTHM, Inc. stock price rises by 23% due to revised trademark and formulation licensing agreement with Green Thumb Industries. The new agreement will pay a fixed $70 million annually starting in 2026, providing a more predictable revenue stream. The chairman stated that this move will strengthen the long-term partnership and support the company's listing on NASDAQ.

LootboxPhobia

2026-04-01 22:33:03

Abstract generation in progress

Investing.com – RYTHM, Inc. (Nasdaq ticker: RYM) shares jumped 23%. Earlier, the company announced revisions to its trademark and recipe license agreement with Green Thumb Industries Inc., an indirectly wholly owned subsidiary.

The revised agreement covers brand intellectual property, including RYTHM, incredibles, Beboe, Dogwalkers, Doctor Solomon’s, &Shine, and Good Green. Effective April 1, 2026, Green Thumb will pay RYTHM a total of $70 million in fixed annual cash fees, which will double each year based on an adjustment factor tied to the Consumer Price Index.

Ben Kovler, Chairman and Interim CEO of RYTHM, Inc., said: “These revisions create a framework that, in the long term, strengthens our licensing arrangements with Green Thumb and supports RYTHM’s listing status on Nasdaq.”

Kovler added that the company has built predictable long-term revenue in a nearly unrivaled way in the THC space. He noted that as the regulatory and legal environment evolves, this structure provides clarity and stability for the business and investors, enabling the company to create maximum value for shareholders.

The revised licensing agreement represents a shift from the prior arrangement to a fixed-fee structure, giving RYTHM a more predictable stream of revenue from its brand portfolio.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes